FATE
Price
$1.75
Change
-$0.13 (-6.91%)
Updated
Dec 18, 12:33 PM (EDT)
75 days until earnings call
VRDN
Price
$20.06
Change
-$0.76 (-3.65%)
Updated
Dec 18, 11:12 AM (EDT)
70 days until earnings call
Ad is loading...

FATE vs VRDN

Header iconFATE vs VRDN Comparison
Open Charts FATE vs VRDNBanner chart's image
Fate Therapeutics
Price$1.75
Change-$0.13 (-6.91%)
Volume$2.3K
CapitalizationN/A
Viridian Therapeutics
Price$20.06
Change-$0.76 (-3.65%)
Volume$400
CapitalizationN/A
FATE vs VRDN Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. VRDN commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and VRDN is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (FATE: $1.88 vs. VRDN: $20.82)
Brand notoriety: FATE and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 93% vs. VRDN: 170%
Market capitalization -- FATE: $214.12M vs. VRDN: $1.65B
FATE [@Biotechnology] is valued at $214.12M. VRDN’s [@Biotechnology] market capitalization is $1.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, VRDN is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 3 TA indicator(s) are bullish while VRDN’s TA Score has 6 bullish TA indicator(s).

  • FATE’s TA Score: 3 bullish, 6 bearish.
  • VRDN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, VRDN is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -17.54% price change this week, while VRDN (@Biotechnology) price change was +7.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.44%, and the average quarterly price growth was +4.25%.

Reported Earning Dates

FATE is expected to report earnings on Mar 03, 2025.

VRDN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.65B) has a higher market cap than FATE($214M). VRDN YTD gains are higher at: -4.408 vs. FATE (-49.733). FATE has higher annual earnings (EBITDA): -177.57M vs. VRDN (-253.41M). VRDN has more cash in the bank: 753M vs. FATE (297M). VRDN has less debt than FATE: VRDN (21.1M) vs FATE (99M). FATE has higher revenues than VRDN: FATE (13.4M) vs VRDN (302K).
FATEVRDNFATE / VRDN
Capitalization214M1.65B13%
EBITDA-177.57M-253.41M70%
Gain YTD-49.733-4.4081,128%
P/E RatioN/AN/A-
Revenue13.4M302K4,437%
Total Cash297M753M39%
Total Debt99M21.1M469%
FUNDAMENTALS RATINGS
FATE vs VRDN: Fundamental Ratings
FATE
VRDN
OUTLOOK RATING
1..100
8162
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
94
Overvalued
PROFIT vs RISK RATING
1..100
10059
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
8841
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (18) in the Biotechnology industry is significantly better than the same rating for VRDN (94). This means that FATE’s stock grew significantly faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (59) in the Biotechnology industry is somewhat better than the same rating for FATE (100). This means that VRDN’s stock grew somewhat faster than FATE’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as VRDN (98). This means that FATE’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for FATE (88). This means that VRDN’s stock grew somewhat faster than FATE’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as FATE (100). This means that VRDN’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEVRDN
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
86%
Bullish Trend 23 days ago
81%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGTRX72.34-0.28
-0.39%
Putnam Global Technology R
CSINX9.05-0.05
-0.55%
Centerstone International C
MSAAX16.02-0.09
-0.56%
Morgan Stanley Inst Passport ovrs eq C
HILTX18.52-0.14
-0.75%
Hartford International Value R5
JSJIX18.11-0.30
-1.63%
JHancock Small Cap Dynamic Growth I

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with ALLO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-3.34%
ALLO - VRDN
52%
Loosely correlated
+0.49%
FATE - VRDN
49%
Loosely correlated
-6.00%
CRBU - VRDN
46%
Loosely correlated
+1.57%
AURA - VRDN
46%
Loosely correlated
-2.47%
ABCL - VRDN
44%
Loosely correlated
-2.45%
More